Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Large Growth in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 24,200 shares, a growth of 70.4% from the July 31st total of 14,200 shares. Based on an average daily volume of 58,900 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Portland Global Advisors LLC grew its position in Global X Genomics & Biotechnology ETF by 0.6% in the first quarter. Portland Global Advisors LLC now owns 242,090 shares of the company’s stock worth $2,755,000 after buying an additional 1,450 shares during the last quarter. Centaurus Financial Inc. boosted its position in shares of Global X Genomics & Biotechnology ETF by 14.6% in the 4th quarter. Centaurus Financial Inc. now owns 12,738 shares of the company’s stock valued at $147,000 after purchasing an additional 1,624 shares during the period. McGuire Investment Group LLC increased its stake in Global X Genomics & Biotechnology ETF by 6.7% in the 1st quarter. McGuire Investment Group LLC now owns 58,651 shares of the company’s stock worth $667,000 after purchasing an additional 3,696 shares in the last quarter. James J. Burns & Company LLC raised its holdings in Global X Genomics & Biotechnology ETF by 35.6% during the 4th quarter. James J. Burns & Company LLC now owns 18,479 shares of the company’s stock worth $214,000 after buying an additional 4,848 shares during the period. Finally, Oppenheimer Asset Management Inc. boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 10.2% in the second quarter. Oppenheimer Asset Management Inc. now owns 67,712 shares of the company’s stock worth $707,000 after buying an additional 6,260 shares during the period. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Down 1.0 %

GNOM stock opened at $11.38 on Friday. The firm has a 50 day simple moving average of $11.13 and a 200-day simple moving average of $10.95. The company has a market capitalization of $84.67 million, a P/E ratio of -4.86 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a twelve month low of $8.63 and a twelve month high of $12.53.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.